TW202302633A - 結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子以及其用途 - Google Patents

結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子以及其用途 Download PDF

Info

Publication number
TW202302633A
TW202302633A TW111120663A TW111120663A TW202302633A TW 202302633 A TW202302633 A TW 202302633A TW 111120663 A TW111120663 A TW 111120663A TW 111120663 A TW111120663 A TW 111120663A TW 202302633 A TW202302633 A TW 202302633A
Authority
TW
Taiwan
Prior art keywords
seq
amino acid
vegf
acid sequence
antibody
Prior art date
Application number
TW111120663A
Other languages
English (en)
Chinese (zh)
Inventor
黎一鳴
胡思怡
荊華
Original Assignee
大陸商信達生物製藥（蘇州）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商信達生物製藥（蘇州）有限公司 filed Critical 大陸商信達生物製藥（蘇州）有限公司
Publication of TW202302633A publication Critical patent/TW202302633A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111120663A 2021-06-04 2022-06-02 結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子以及其用途 TW202302633A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110623779.2 2021-06-04
CN202110623779 2021-06-04

Publications (1)

Publication Number Publication Date
TW202302633A true TW202302633A (zh) 2023-01-16

Family

ID=84323888

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111120663A TW202302633A (zh) 2021-06-04 2022-06-02 結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子以及其用途

Country Status (11)

Country Link
US (1) US20240247057A1 (https=)
EP (1) EP4349861A4 (https=)
JP (1) JP2024520693A (https=)
KR (1) KR20240023095A (https=)
CN (1) CN117500828A (https=)
AU (1) AU2022287100A1 (https=)
CA (1) CA3221192A1 (https=)
IL (1) IL309035A (https=)
MX (1) MX2023014407A (https=)
TW (1) TW202302633A (https=)
WO (1) WO2022253314A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3231417A1 (en) * 2021-09-10 2023-03-16 Jian Shi Anti-ang2 antibody, preparation method therefor, and application thereof
IL321122A (en) * 2022-12-01 2025-07-01 Innovent Biologics Suzhou Co Ltd Formulations containing dual-specific binding molecules that bind VEGF and ANG2 and their uses
WO2025151018A1 (ko) * 2024-01-12 2025-07-17 주식회사 노벨티노빌리티 C-kit 및 vegf에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
WO2025228314A1 (en) * 2024-04-29 2025-11-06 Shenzhen Oculgen Biomedical Technology Co., Ltd Ang2/vegf bispecific binding molecules
WO2026037352A1 (zh) * 2024-08-13 2026-02-19 长春金赛药业有限责任公司 同时结合VEGF及Ang-2的Fc融合蛋白及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
SG11201408538PA (en) 2012-07-13 2015-02-27 Roche Glycart Ag Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
WO2016073157A1 (en) * 2014-11-06 2016-05-12 Genentech, Inc. Anti-ang2 antibodies and methods of use thereof
BR112017009764A2 (pt) * 2014-11-10 2018-02-20 Hoffmann La Roche anticorpos biespecíficos e métodos de uso em oftalmologia
MA49279A (fr) * 2017-03-22 2020-02-05 Hoffmann La Roche Compositions d'anticorps optimisées pour le traitement de troubles oculaires
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2

Also Published As

Publication number Publication date
CN117500828A (zh) 2024-02-02
US20240247057A1 (en) 2024-07-25
EP4349861A1 (en) 2024-04-10
IL309035A (en) 2024-02-01
AU2022287100A1 (en) 2024-01-25
MX2023014407A (es) 2024-04-23
WO2022253314A1 (zh) 2022-12-08
CA3221192A1 (en) 2022-12-08
KR20240023095A (ko) 2024-02-20
EP4349861A4 (en) 2025-07-23
JP2024520693A (ja) 2024-05-24

Similar Documents

Publication Publication Date Title
TW202302633A (zh) 結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子以及其用途
RU2765306C2 (ru) Антитело против в7-н3, его антигенсвязывающий фрагмент и их медицинское применение
US20220235123A1 (en) Synthetic antibodies against vegf and their uses
KR20210141992A (ko) Vegf 및 ang2에 특이적으로 결합되는 이중특이적 항체
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
JP2024518724A (ja) 抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
KR20250139273A (ko) 삼중특이적 융합 단백질 및 이의 용도
JP2024529119A (ja) 抗ｖｅｇｆａとｖｅｇｆｃ二重特異性抗体およびその使用
CN108101986A (zh) 抗vegf抗体
TW202426052A (zh) 包含結合ｖｅｇｆ和ａｎｇ２的雙特異性結合分子的製劑以及其用途
JP7804295B2 (ja) 二機能性融合タンパク質およびその用途
KR20220069076A (ko) 항-nrp1a 항체와 안구 또는 안구 질환 치료를 위한 이의 용도
WO2024165077A1 (zh) 一种包含抗vegfa和vegfc双特异性结合蛋白的药物制剂
KR20250130525A (ko) 신규한 항-Ang-2 항체 및 이의 용도
TW202436360A (zh) 抗ａｎｇ２抗體及其製備方法和應用
WO2025119329A1 (zh) 抗c5和htra1双特异性抗体及其用途
JP2024506664A (ja) 抗ｖｅｇｆ抗体およびその使用
CN120418286A (zh) TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
CN116478288A (zh) 红细胞弱结合型人源化cd47抗体及其应用